Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Income from Continuing Operations: 2023-2024

Historic Income from Continuing Operations for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $1.7 billion.

  • Inhibrx Biosciences' Income from Continuing Operations rose 19.62% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 109.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 803.96% up from last year.
  • Inhibrx Biosciences' Income from Continuing Operations amounted to $1.7 billion in FY2024, which was up 803.96% from -$239.7 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Income from Continuing Operations ranged from a high of $1.7 billion in FY2024 and a low of -$239.7 million during FY2023.
  • Moreover, its 2-year median value for Income from Continuing Operations was $723.9 million (2023), whereas its average is $723.9 million.
  • Data for Inhibrx Biosciences' Income from Continuing Operations shows a peak YoY spiked of 803.96% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Income from Continuing Operations (Yearly) stood at -$239.7 million in 2023, then spiked by 803.96% to $1.7 billion in 2024.